The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial
Open accessAbstract
The surface Ig on each B-cell lymphoma has unique portions (idiotypes), which can be recognized by the immune system. In this study, we immunized patients against the Ig expressed by their tumor and observed their clinical outcomes. After standard chemotherapy, 41 patients with non-Hodgkin's B-cell lymphoma received a series of injections with a vaccine consisting of tumor Ig protein coupled to keyhole limpet hemocyanin and emulsified in an immunologic adjuvant. Subjects were observed for toxicity, immune responses, and tumor status. The median duration of follow-up of all patients is 7.3 years from diagnosis and 5.3 years from the last chemotherapy given before vaccine treatment. Twenty patients (49%) generated specific immune responses against the idiotypes of their tumor Ig. Two patients who had residual disease experienced complete tumor regression in association with the development of these immune responses. The median duration of freedom from disease progression and overall survival of all 20 patients mounting an anti-idiotype immune response are significantly prolonged compared to the patients who did not mount an immune response. Thirty-two patients were in their first remission and nine were in subsequent remissions before beginning vaccine treatments. Analysis of the 32 first remission patients also shows an improved clinical outcome for those patients who mounted a specific immune response compared to those who did not (freedom from progression, 7.9 years v 1.3 years P = .0001; median survival from time of last chemotherapy not yet reached v 7 years, P = .04). This study confirms an earlier report that patients with B-cell lymphoma can be induced to make a specific immune response against the Ig expressed by their own tumor. It further shows that the ability to make such an immune response is correlated with a more favorable clinical outcome. Prospective controlled trials will be needed to prove a causal relationship between anti-idiotype immunity and improved clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Non-Hodgkin's Lymphoma Pathologic Classification Project (1982) · Cancer · doi:10.1002/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2 · Cited by 3,059
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Self-citationTreatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody
Miller, R. A., Maloney, D. G., Warnke, R., & Levy, R. (1982) · New England Journal of Medicine · doi:10.1056/nejm198203043060906 · Cited by 985
Self-citationKwak, L. W., Campbell, M. J., Czerwinski, D. K., Hart, S., Miller, R. A., & Levy, R. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210223271705 · Cited by 533
Self-citationA clinical trial of anti-idiotype therapy for B cell malignancy
Meeker, T., Lowder, J., Maloney, D., Miller, R., Thielemans, K., Warnke, R., & Levy, R. (1985) · Blood · doi:10.1182/blood.v65.6.1349.bloodjournal6561349 · Cited by 416
Self-citationTao, M.-H., & Levy, R. (1993) · Nature · doi:10.1038/362755a0 · Cited by 302
Self-citationClonal evolution of a follicular lymphoma: evidence for antigen selection.
Bahler, D. W., & Levy, R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.6770 · Cited by 241
Self-citationBrown, S., Miller, R., Horning, S., Czerwinski, D., Hart, S., McElderry, R., Basham, T., Warnke, R., Merigan, T., & Levy, R. (1989) · Blood · doi:10.1182/blood.v73.3.651.651 · Cited by 175
Self-citationMouse × human heterohybridomas as fusion partners with human B cell tumors
Carroll, W. L., Thielemans, K., Dilley, J., & Levy, R. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90032-3 · Cited by 165
Self-citationCampbell, M. J., Esserman, L. J., Byars, N. E., ALLISON, A. C., & Levy, R. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.3.1029 · Cited by 143
Self-citationLynch, R. G., Rohrer, J. W., Odermatt, B. F., Gebel, H. M., Autry, J. R., & Hoover, R. G. (1979) · Immunological Reviews · doi:10.1111/j.1600-065x.1979.tb00298.x · Cited by 137
Nelson, E. L., Li, X., Hsu, F. J., Kwak, L. W., Levy, R., Clayberger, C., & Krensky, A. M. (1996) · Blood · doi:10.1182/blood.v88.2.580.bloodjournal882580 · Cited by 133
Self-citationChen, T.-T., Tao, M., & Levy, R. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.10.4775 · Cited by 127
Self-citationPreferential use of the VH4 Ig gene family by diffuse large-cell lymphoma
Hsu, F. J., & Levy, R. (1995) · Blood · doi:10.1182/blood.v86.8.3072.3072 · Cited by 124
Self-citationIdiotypic vaccination as a treatment for a B cell lymphoma.
George, A. J. T., FOLKARD, S. G., Hamblin, T. J., & Stevenson, F. K. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.6.2168 · Cited by 113
Vuist, W. M. J., Levy, R., & Maloney, D. G. (1994) · Blood · doi:10.1182/blood.v83.4.899.899 · Cited by 110
Self-citationMaloney, D. G., Kaminski, M. S., BUROWSKI, D., Haimovich, J., & Levy, R. (1985) · Hybridoma · doi:10.1089/hyb.1985.4.191 · Cited by 110
Self-citationCampbell, M. J., Esserman, L. J., & Levy, R. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.9.3227 · Cited by 90
Self-citationMaloney, D. G., Brown, S. L., Czerwinski, D. K., Liles, T. M., Hart, S. M., Miller, R., & Levy, R. (1992) · Blood · doi:10.1182/blood.v80.6.1502.1502 · Cited by 78
Self-citationClinical Trials of Idiotype‐Specific Vaccine in B‐Cell Lymphomas
Hsu, F. J., Kwak, L. W., Campbell, M. J., Liles, T. M., Czerwinski, D. K., Hart, S., Syrengelas, A. D., Miller, R. A., & Levy, R. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb44039.x · Cited by 42
Self-citation
Cited by
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
Van den Eynde, B. J., & van der Bruggen, P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80050-7 · Cited by 623
Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., et al. (1999) · Nature Medicine · doi:10.1038/13928 · Cited by 594
Self-citationTimmerman, J. M., Czerwinski, D. K., Davis, T. A., Hsu, F. J., Benike, C., Hao, Z. M., Taidi, B., Rajapaksa, R., Caspar, C. B., Okada, C. Y., et al. (2002) · Blood · doi:10.1182/blood.v99.5.1517 · Cited by 545
Self-citationWeiner, G. J., Liu, H.-M., Wooldridge, J. E., Dahle, C. E., & Krieg, A. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10833 · Cited by 519
Metadata
- Authors
- Hsu, F. J., Caspar, C. B., Czerwinski, D., Kwak, L. W., Liles, T. M., Syrengelas, A., Taidi-Laskowski, B., & Levy, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1997-05-01
- Volume
- 89
- Issue
- 9
- Pages
- 3129-3135
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W177504901
- Cited by
- 452
- References
- 20
- FWCI
- 18.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.